A report developed by Avalere Health, based on a survey that the company conducted among health plans in 2015, states that a majority of health plans want to sign outcomes-based contracts with biopharmaceutical companies, especially for oncology and hepatitis C drugs.
A report developed by Avalere Health, based on a survey that the company conducted among health plans in 2015, states that a majority of health plans want to sign outcomes-based contracts with biopharmaceutical companies, especially for oncology and hepatitis C drugs. Rheumatoid arthritis and multiple sclerosis were some other therapeutic areas for which insurance companies would like to see outcomes-based contracts.
These kind of contracts have the potential to significantly impact drug prices, especially in oncology, where indication-based pricing models are also being discussed. Under terms of outcomes-based contracting, a health plan gets an additional discount on the drug price if the medicine does not deliver the promised outcomes in patients.
Avalere conducted the survey in March 2015 among 42 health plans in the United States, which cover 161 million individuals. These included 2 integrated health systems, 10 national plans, and 20 regional/state plans. The survey found that health plans have significant interest in negotiating outcomes-based prices for specialty and a few non-specialty areas as well:
Disease
High interest
Very high interest
Hepatitis C
40%
23%
Oncology
33%
20%
Multiple sclerosis
20%
15%
Rheumatoid arthritis
28%
13%
Hemophilia
5%
7%
IBD
18%
5%
HIV
15%
5%
Growth deficiency
5%
IBD indicated irritable bowel disease.
According to Avalere, the need for real-world evidence of patient outcomes, cost and appropriate use of different treatments are leading health plans and manufacturers to look toward different agreement options to help them manage risk and improve predictability of meeting cost and quality targets. Experts at Avalere believe that these terms could prove beneficial to manufacturers, health plans, and providers. Additionally, it can promote strategic treatment plans as stakeholders will make efforts to select the right patient population who will derive the most benefit from a specific treatment.
The interest in outcomes-based contracts is “dramatically accelerating right now because the data is available, and it’s getting much easier to track drug performance,” Dan Mendelson, president at Avalere Health, told STAT News. “In fact, more plans are starting to demand it.” However, barriers remain, the leading ones being reaching an agreement on data sources and measurement of outcomes used in the analysis.
Health plans like Cigna have been moving in this direction—the company recently reached separate agreements with Amgen and Sanofi-Regeneron for each of their new anti-cholesterol agents, evolocumab and alirocumab, respectively.
“Despite the difficulties that plans and drug manufacturers may face when entering into a risk-based contracts, there are opportunities for all stakeholders involved to benefit in the end,” according to Kathy Hughes, vice president at Avalere. “Coming to agreement on all of aspects of a contract—design,management, payment, implementation, and data collection—is a difficult but necessary process that requires the full commitment of both parties.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More